AQST

Aquestive Therapeutics Inc. (AQST) | Rumor.io

Aquestive Therapeutics

AQST

Attention (50-day avg)0%

Attention rank (50-day avg)#683

Bullish sentiment (50-day avg)86%

Price to earnings ratio-6.08

Market capitalization596.2M

Earnings per share-0.66

Dividend yield (TTM)—

Revenue (annual)44.5M

Net income (annual)-83.8M

Social

What share of all stock conversation is about AQST?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0.01% -0.01

Sep 29

Aquestive Therapeutics has appointed Richard J. Daly as a new director, effective October 14, 2026, with Daly receiving 57,000 stock options as part of his compensation.
The appointment of Daly is seen as a signal that the company is preparing for a strong drug rollout and may go it alone post approval, with some analysts viewing the company as a "winner".
The stock has been subject to high short interest and declining sentiment, with one analyst suggesting it may be a good time to buy due to its potential upside, but another warning of a potential larger hit due to rising interest rates.

Generated by AI

Sentiment

Of the messages about AQST that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% new	76.27% -9.16	79.82% -14.16	75.73% -5.42
Bearish	0% -100	23.73% +9.16	20.18% +14.16	24.27% +5.42

Bullish· Sep 17

The company's market cap is relatively low at just over $600 million, making it an attractive target for a potential buyout in the $2 billion range.
The FDA has 60 days to review the resubmitted NDA application, which could lead to a PDUFA date and potentially significant price appreciation.
The company's Libervant US partnership, set to launch in January 2027, could bring in a huge upfront payment and significant revenues from manufacturing, making it a key catalyst for the stock's price.

Bearish· Jun 29

Aquestive Therapeutics, Inc. (AQST) has dropped to $4.39, a decline of -1.68%, causing significant pain for investors.
The company's stock price has fallen by $1 in a week, indicating a sustained downward trend.
The decline in AQST's stock price may be attributed to a lack of positive news, with some investors viewing the stock as unattractive due to its recent performance.

Generated by AI

Topics

Of the messages about AQST that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	40%	77.85%	20.45%
Technical Analysis	—	60%	16.78%	13.97%
Earnings	—	0%	1.34%	8.69%
Analysts	—	0%	2.01%	31.89%
Macro	—	0%	2.01%	23.35%
Controversies	—	0%	0%	1.66%

Earnings· Nov 5

Aquestive Therapeutics reported a loss of $0.54 per share, beating consensus estimates of a loss of $0.78.
The company raised its 2019 guidance following its third quarter financial results.
Aquestive Therapeutics' third quarter revenue of $12.42M beat estimates by $2.26M.

Analysts· May 16

Aquestive Therapeutics, Inc. (AQST) is a pharmaceutical company that develops orally administered products to simplify complex delivery methods and treat diseases of the central nervous system and severe allergic reactions.
Aquestive has a late-stage proprietary product pipeline and an earlier stage pipeline for treating diseases and severe allergic reactions, aiming to advance current standards of care.
Analysts' opinions on Aquestive Therapeutics are mixed, with some rating the stock as a Buy and others as a Hold, but no specific information on Aquestive is provided in the given posts.

Announcements· Feb 2

Aquestive Therapeutics (AQST) received a Complete Response Letter from the FDA for its oral drug Anaphylm, citing deficiencies in packaging and administration.
The company plans to resubmit the application in Q3 2026 and remains well-capitalized, expecting to end 2026 with significant cash.
The FDA's decision marks a setback for AQST's push to bring a convenient, oral treatment option for severe allergic reactions, potentially giving ARS Pharma's Neffy a window to solidify its position in the market.

Technical Analysis· Feb 2

$AQST has reclaimed the $4.00 level and its VWAP, suggesting a potential reversal in price.
The Relative Strength (RS) of $AQST remains high, with buyers continuing to support price on pullbacks, indicating an intact trend.
The 200-day moving average of $AQST is at $4.52, and a potential break above this level could lead to further price gains.

Generated by AI

Community

Of the messages about AQST, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	97.2%	93.81%	82.9%
Newcomers	0%	2.8%	6.19%	17.1%

Regulars· Sep 29

The appointment of Richard J. Daly as a new director on the Aquestive Therapeutics board may signal that the company is preparing to go it alone after approval, as he was added to the board despite already having a strong team in place.
Aquestive's leadership team inspires confidence, and the company's focus on preparing for a strong drug rollout is a positive sign for investors.
The recent addition of Richard J. Daly to the board may indicate that the company is preparing to move forward with its drug, Anaphylm, and is taking steps to ensure a successful rollout.

Newcomers· Aug 11

Analysts raised revenue estimates ahead of Q2 earnings, leading to a 6.74% surge in $AQST.
Aquestive Therapeutics' Anaphylm™ has shown positive results in human factors and pharmacokinetic studies, with a planned NDA resubmission for Q3 2026.
The company's approval data is seen as "baked in," with investors expecting a "show me" phase for commercialization, as long as there is no hidden adverse data management.

Generated by AI

News

Aquestive appoints Rich Daly to board of directors

1d agoInvesting.com

Aquestive Therapeutics Resubmits FDA Application for Pocket-Sized Allergy Treatment

12d agoBenzinga

Aquestive resubmits drug application for anaphylaxis treatment

13d agoInvesting.com

Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026FDA will determine the resubmission classification and establish the applicable review timeline following its initial review of the resubmission WARREN, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innova

13d agoYahoo Finance

Aquestive Therapeutics CEO Barber sells $120,487 in shares

13d agoInvesting.com

Aquestive at H.C. Wainwright conference: anaphylm launch in focus

15d agoInvesting.com

Also Discussed

Investors talking about AQST also mention

#	Name	Attention
1	Ars Pharmaceuticals IncSPRY	0%0
2	Iovance Biotherapeutics Inc.IOVA	1.03%+0.91
3	DAWN - Day One Biopharmaceuticals, Inc.	——
4	Grace Therapeutics, Inc.GRCE	0%new
5	Arcutis Biotherapeutics, Inc.ARQT	0%+0
6	Eton Pharmaceuticals, Inc.ETON	0%0
7	Replimune Group, Inc.REPL	0%0
8	Ardelyx IncARDX	0.01%+0.01
9	TERN - Terns Pharmaceuticals, Inc.	——
10	Fortress Biotech, Inc.FBIO	0%0

Aquestive Therapeutics Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Aquestive Therapeutics Inc. is a specialty pharmaceutical company focused on developing and commercializing oral and non-invasive drug-delivery therapies. The company’s portfolio includes approved products such as Libervant for seizure clusters, along with licensed medicines delivered through its proprietary PharmFilm technology. This platform is designed to simplify administration of complex treatments using thin-film formulations that dissolve in the mouth, supporting use cases where traditional pills, injections, or infusions may be less practical. Aquestive Therapeutics also operates as a contract development and manufacturing partner, producing and packaging pharmaceutical products for licensees and customers. Its business is centered on central nervous system therapies, emergency allergy treatments, and other conditions where alternative delivery methods can improve usability and access to care. Headquartered in Warren, New Jersey, Aquestive Therapeutics plays a niche role in the broader pharmaceutical market through differentiated formulation science and specialized manufacturing capabilities.

Website

Location

30 Technology Drive

Warren, NJ, 07059

United States

Social

What share of all stock conversation is about AQST?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0.01% -0.01

Sep 29

Aquestive Therapeutics has appointed Richard J. Daly as a new director, effective October 14, 2026, with Daly receiving 57,000 stock options as part of his compensation.
The appointment of Daly is seen as a signal that the company is preparing for a strong drug rollout and may go it alone post approval, with some analysts viewing the company as a "winner".
The stock has been subject to high short interest and declining sentiment, with one analyst suggesting it may be a good time to buy due to its potential upside, but another warning of a potential larger hit due to rising interest rates.

Generated by AI

Sentiment

Of the messages about AQST that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% new	76.27% -9.16	79.82% -14.16	75.73% -5.42
Bearish	0% -100	23.73% +9.16	20.18% +14.16	24.27% +5.42

Bullish· Sep 17

The company's market cap is relatively low at just over $600 million, making it an attractive target for a potential buyout in the $2 billion range.
The FDA has 60 days to review the resubmitted NDA application, which could lead to a PDUFA date and potentially significant price appreciation.
The company's Libervant US partnership, set to launch in January 2027, could bring in a huge upfront payment and significant revenues from manufacturing, making it a key catalyst for the stock's price.

Bearish· Jun 29

Aquestive Therapeutics, Inc. (AQST) has dropped to $4.39, a decline of -1.68%, causing significant pain for investors.
The company's stock price has fallen by $1 in a week, indicating a sustained downward trend.
The decline in AQST's stock price may be attributed to a lack of positive news, with some investors viewing the stock as unattractive due to its recent performance.

Generated by AI

Topics

Of the messages about AQST that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	40%	77.85%	20.45%
Technical Analysis	—	60%	16.78%	13.97%
Earnings	—	0%	1.34%	8.69%
Analysts	—	0%	2.01%	31.89%
Macro	—	0%	2.01%	23.35%
Controversies	—	0%	0%	1.66%

Earnings· Nov 5

Aquestive Therapeutics reported a loss of $0.54 per share, beating consensus estimates of a loss of $0.78.
The company raised its 2019 guidance following its third quarter financial results.
Aquestive Therapeutics' third quarter revenue of $12.42M beat estimates by $2.26M.

Analysts· May 16

Aquestive Therapeutics, Inc. (AQST) is a pharmaceutical company that develops orally administered products to simplify complex delivery methods and treat diseases of the central nervous system and severe allergic reactions.
Aquestive has a late-stage proprietary product pipeline and an earlier stage pipeline for treating diseases and severe allergic reactions, aiming to advance current standards of care.
Analysts' opinions on Aquestive Therapeutics are mixed, with some rating the stock as a Buy and others as a Hold, but no specific information on Aquestive is provided in the given posts.

Announcements· Feb 2

Aquestive Therapeutics (AQST) received a Complete Response Letter from the FDA for its oral drug Anaphylm, citing deficiencies in packaging and administration.
The company plans to resubmit the application in Q3 2026 and remains well-capitalized, expecting to end 2026 with significant cash.
The FDA's decision marks a setback for AQST's push to bring a convenient, oral treatment option for severe allergic reactions, potentially giving ARS Pharma's Neffy a window to solidify its position in the market.

Technical Analysis· Feb 2

$AQST has reclaimed the $4.00 level and its VWAP, suggesting a potential reversal in price.
The Relative Strength (RS) of $AQST remains high, with buyers continuing to support price on pullbacks, indicating an intact trend.
The 200-day moving average of $AQST is at $4.52, and a potential break above this level could lead to further price gains.

Generated by AI

Community

Of the messages about AQST, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	97.2%	93.81%	82.9%
Newcomers	0%	2.8%	6.19%	17.1%

Regulars· Sep 29

The appointment of Richard J. Daly as a new director on the Aquestive Therapeutics board may signal that the company is preparing to go it alone after approval, as he was added to the board despite already having a strong team in place.
Aquestive's leadership team inspires confidence, and the company's focus on preparing for a strong drug rollout is a positive sign for investors.
The recent addition of Richard J. Daly to the board may indicate that the company is preparing to move forward with its drug, Anaphylm, and is taking steps to ensure a successful rollout.

Newcomers· Aug 11

Analysts raised revenue estimates ahead of Q2 earnings, leading to a 6.74% surge in $AQST.
Aquestive Therapeutics' Anaphylm™ has shown positive results in human factors and pharmacokinetic studies, with a planned NDA resubmission for Q3 2026.
The company's approval data is seen as "baked in," with investors expecting a "show me" phase for commercialization, as long as there is no hidden adverse data management.

Generated by AI

Aquestive Therapeutics

Social

Sep 29

Bullish· Sep 17

Bearish· Jun 29

Earnings· Nov 5

Analysts· May 16

Announcements· Feb 2

Technical Analysis· Feb 2

Regulars· Sep 29

Newcomers· Aug 11

Aquestive appoints Rich Daly to board of directors

Aquestive Therapeutics Resubmits FDA Application for Pocket-Sized Allergy Treatment

Aquestive resubmits drug application for anaphylaxis treatment

Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

Aquestive Therapeutics CEO Barber sells $120,487 in shares

Aquestive at H.C. Wainwright conference: anaphylm launch in focus

Also Discussed

Aquestive Therapeutics Inc.

Company Information

Location

Aquestive appoints Rich Daly to board of directors

Aquestive Therapeutics Resubmits FDA Application for Pocket-Sized Allergy Treatment

Aquestive resubmits drug application for anaphylaxis treatment

Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

Aquestive Therapeutics CEO Barber sells $120,487 in shares

Aquestive at H.C. Wainwright conference: anaphylm launch in focus

Also Discussed

Social

Sep 29

Bullish· Sep 17

Bearish· Jun 29

Earnings· Nov 5

Analysts· May 16

Announcements· Feb 2

Technical Analysis· Feb 2

Regulars· Sep 29

Newcomers· Aug 11